外科理论与实践

外科理论与实践 >

2022 , Vol. 27 >Issue 03: 256 - 260

DOI: https://doi.org/10.16139/j.1007-9610.2022.03.015

综述

肠道菌群与肝癌的发病机制

展开
  • 上海交通大学医学院附属瑞金医院外科,上海 200025

收稿日期: 2021-08-16

  网络出版日期: 2022-08-03

收起

Gut microbiota and mechanism of liver cancer

Expand
  • Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2021-08-16

  Online published: 2022-08-03

Fold

摘要

我国肝癌发病率高,新发病例占全球46.7%,死亡病例占47.1%。肝癌发病与肝炎病毒、黄曲霉素、饮酒等危险因素相关。近年对肠道菌群研究日渐深入,显示肠道菌群在肝癌发生、发展中的作用。本文从菌群移位、肠源性内毒素血症和细菌代谢产物变化探讨肝癌与肠道菌群的关系,并从益生菌、粪便菌群移植、抗生素以及Toll样受体4拮抗剂途径探索经肠道菌群治疗肝癌的新思路。

关键词： 肠道菌群; 肝癌; 肠-肝轴

本文引用格式

陈聪燕 综述, 王俊青, 陈拥军 审校 . 肠道菌群与肝癌的发病机制[J]. 外科理论与实践, 2022 , 27(03) : 256 -260 . DOI: 10.16139/j.1007-9610.2022.03.015

Abstract

Liver cancer incidence in China is higher with new cancer cases accounted for 46.7% of global prevalence and death cases 47.1%. Hepatic virus, aflatoxin and alcohol drinking are the risk factors associated with the mechanism of liver cancer. Study on gut microbiota in recent years was ongoing deeply, indicating gut microbiota associated with the development of liver cancer. Liver cancer with gut microbiota was studied in this paper for microbiota displacement, intestinal endotoxemia, and changes in bacterial metabolite, including the new ideas in treatment of liver cancer via gut microbiota from probiotics, fecal microbiota transplantation, antibiotics and Toll-like receptor 4 antagonist pathways.

Key words： Gut microbiota; Liver cancer; Gut-liver axis

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Ying Q, Wang Y. Global prevalence and trend of liver cancer[J]. China Cancer, 2020, 29(3):185-191.
[3] He X, Ji G, Jia W, et al. Gut microbiota and nonalcoholic fatty liver disease: insights on mechanism and application of metabolomics[J]. Int J Mol Sci, 2016, 17(3):300.
[4] Meroni M, Longo M, Dongiovanni P. Alcohol or gut microbiota: who is the guilty?[J]. Int J Mol Sci, 2019, 20(18):4568.
[5] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastro Hepat, 2018, 15(7):397-411.
[6] Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis[J]. JCI Insight, 2017, 2(19):e94416.
[7] Ding T, Scholoss PD. Dynamics and associations of microbial community types across the human body[J]. Nature, 2014, 509(7500):357-360.
[8] Ma Q, Li Y, Li P, et al. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora[J]. Biomed Pharmacother, 2019, 117:109-138.
[9] Gomes AC, Hoffmann C, Mota JF. The human gut microbiota: metabolism and perspective in obesity[J]. Gut Microbes, 2018, 9(4):308-325.
[10] Huang P, Liu Y. A reasonable diet promotes balance of intestinal microbiota: prevention of precolorectal cancer[J]. Biomed Res Int, 2019, 2019:3405278.
[11] Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J]. Hepatol, 2019, 69(1):107-120.
[12] Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma[J]. Liver Transpl, 2020, 26(10):1316-1327.
[13] Zhang HL, Yu LX, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats - Science Direct[J]. J Hepatol, 2012, 57(4):803-812.
[14] Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J]. Nature, 2012, 482:179-185.
[15] Fedirko V, Tran HQ, Gewirtz AT, et al. Exposure to bacterial products lipopolysaccharide and flagellin and he-patocellular carcinoma: a nested case-control study[J]. BMC Med, 2017, 15(1):72.
[16] Ponziani FR, Nicoletti A, Gasbarrini A, et al. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2019, 11:1-16.
[17] Dapito D, Mencin A, Gwak GY, et al. Promotion of he-patocellular carcinoma by the intestinal microbiota and TLR4[J]. Cancer Cell, 2012, 21(4):504-516.
[18] Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(9):527-539.
[19] Yoshimoto S, Loo T, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J]. Nature, 2013, 499:97-101.
[20] Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites[J]. Gut, 2021, 70(4):761-774.
[21] Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360(6391):eaan5931.
[22] Chen T, Kim CY, Kaur A, et al. Dietary fibre-based SCFA mixtures promote both protection and repair of intestinal epithelial barrier function in a Caco-2 cell model[J]. Food Func, 2017, 8(3):1166-1173.
[23] Feng Q, Chen WD, Wang YD. Gut microbiota: an integral moderator in health and disease[J]. Front Microbiol, 2018, 9:151.
[24] Jia W, Rajani C, Xu H, et al. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma[J]. Protein Cell, 2021, 12(5):374-494.
[25] Weitkunat K, Stuhlmann C, Postel A, et al. Short-chain fatty acids and inulin, but not guar gum, prevent diet-induced obesity and insulin resistance through differential mechanisms in mice[J]. Sci Rep, 2017, 7(1):6109.
[26] Javanmard A, Ashtari S, Sabet B, et al. Probiotics and their role in gastrointestinal cancers prevention and treatment; an overview[J]. Gastroenterol Hepatol Bed Bench, 2018, 11(4):284-295.
[27] Li J, Sung CYJ, Lee N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J]. Proc Natl Acad Sci USA, 2016, 113(9):1306-1315.
[28] Li J, Sung CY, Lee N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J]. Proc Natl Acad Sci USA, 2016, 113(9):E1306-E1315.
[29] Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial[J]. Gastroenterol, 2014, 147(6):1327-1337.
[30] Kumar M, Verma V, Nagpal R, et al. Effect of probiotic fermented milk and chlorophyllin on gene expressions and genotoxicity during AFB-induced hepatocellular carcinoma[J]. Gene, 2011, 490(1-2):54-59.
[31] Zhou A, Tang L, Zeng S, et al. Gut microbiota: a new piece in understanding hepatocarcinogenesis[J]. Cancer Letters, 2020, 474:15-22.
[32] Grander C, Adolph TE, Wieser V, et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ame-liorates alcoholic liver disease[J]. Gut, 2018, 67(5):891-901.
[33] Han SH, Suk KT, Kim DJ, et al. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study[J]. Eur J Gastroenterol Hepatol, 2015, 27(11):1300-1306.
[34] Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis[J]. Aliment Pharm Ther, 2014, 39:1113-1125.
[35] Wang P, Chen K. Gut microbiota and hepatocellular carcinoma[J]. Hepatobil Surg Nutr, 2020, 9(3):345-347.
[36] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma[J]. Gut, 2019, 68(6):1014-1023.
[37] Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J]. J Immunother Cancer, 2019, 7(1):193.
[38] Calanni F, Renzulli C, Barbanti M, et al. Rifaximin: beyond the traditional antibiotic activity[J]. J Antibiot, 2014, 67(9):667-670.
[39] Peri F, Piazza M. Therapeutic targeting of innate immunity with Toll-like receptor 4(TLR4) antagonists[J]. Biotechnol Adv, 2012, 30(1):251-260.
Options
文章导航

/

〈 〉